Atea Pharmaceuticals, Inc. (AVIR)

Market Cap	377.38M
Revenue (ttm)	n/a
Net Income (ttm)	-109.30M
Shares Out	83.40M
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,289
Open	4.46
Previous Close	4.50
Day's Range	4.45 - 4.59
52-Week Range	2.94 - 9.79
Beta	0.24
Analysts	Hold
Price Target	6.00 (+32.16%)
Earnings Date	May 8, 2023

About AVIR

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formula...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 30, 2020
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: AVIR

Analyst Forecast

According to 3 analysts, the average rating for AVIR stock is "Hold." The 12-month stock price forecast is $6.0, which is an increase of 32.16% from the latest price.

Price Target

$6.0

(32.16% upside)

Analyst Consensus: Hold